FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035922182> ?p ?o ?g. }

• W3035922182 endingPage "227" @default.
• W3035922182 startingPage "220" @default.
• W3035922182 abstract "Phase 3 trials have demonstrated the safety and efficacy of lumacaftor-ivacaftor (LUMA-IVA) in patients with cystic fibrosis (CF) homozygous for the Phe508del CFTR mutation and percent predicted forced expiratory volume in 1 s (ppFEV1) between 40 and 90. Marketing authorizations have been granted for patients at all levels of ppFEV1.To evaluate the safety and effectiveness of LUMA-IVA over the first year of treatment in patients with ppFEV1<40 or ppFEV1≥90 in comparison with those with ppFEV1 [40-90[. Analysis of data collected during a real world study, which included all patients aged ≥12 years who started LUMA-IVA in 2016 across all 47 French CF centers.827 patients were classified into 3 subgroups according to ppFEV1 at treatment initiation (ppFEV1<40, n = 121; ppFEV1 [40-90[, n = 609; ppFEV1≥90, n = 97). Treatment discontinuation rate was higher in ppFEV1<40 patients (28.9%) than in those with ppFEV1 [40-90[(16.4%) or ppFEV1≥90 (17.5%). In patients with uninterrupted treatment, significant increase in ppFEV1 occurred in the ppFEV1 [40-90[subgroup (+2.9%, P<0.001), and in those ppFEV1<40 (+0.5%, P = 0.03) but not in those with ppFEV1≥90 (P = 0.46). Compared with the year prior to initiation, the number of days of intravenous antibiotics were reduced in all subgroups, although 72% of patients with ppFEV1<40 still experienced at least one exacerbation/year under LUMA-IVA. Comparable increase in body mass index was seen in the three subgroups.Phe508del homozygous CF patients benefit from LUMA-IVA at all levels of baseline lung function, but the characteristics and magnitude of the response vary depending on ppFEV1 at baseline." @default.
• W3035922182 created "2020-06-25" @default.
• W3035922182 creator A5002444114 @default.
• W3035922182 creator A5004678833 @default.
• W3035922182 creator A5006526044 @default.
• W3035922182 creator A5006649224 @default.
• W3035922182 creator A5007768330 @default.
• W3035922182 creator A5011296918 @default.
• W3035922182 creator A5014092783 @default.
• W3035922182 creator A5018306210 @default.
• W3035922182 creator A5018597500 @default.
• W3035922182 creator A5022125342 @default.
• W3035922182 creator A5022662991 @default.
• W3035922182 creator A5025602133 @default.
• W3035922182 creator A5028801971 @default.
• W3035922182 creator A5034520115 @default.
• W3035922182 creator A5050010383 @default.
• W3035922182 creator A5058612089 @default.
• W3035922182 creator A5070019992 @default.
• W3035922182 creator A5071401837 @default.
• W3035922182 creator A5072667906 @default.
• W3035922182 creator A5083476802 @default.
• W3035922182 creator A5087522944 @default.
• W3035922182 creator A5087945072 @default.
• W3035922182 date "2021-03-01" @default.
• W3035922182 modified "2023-10-17" @default.
• W3035922182 title "Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function" @default.
• W3035922182 cites W1589654967 @default.
• W3035922182 cites W1985248538 @default.
• W3035922182 cites W2068994162 @default.
• W3035922182 cites W2112074177 @default.
• W3035922182 cites W2155432663 @default.
• W3035922182 cites W2337762305 @default.
• W3035922182 cites W2400611618 @default.
• W3035922182 cites W2419518172 @default.
• W3035922182 cites W2596109810 @default.
• W3035922182 cites W2607214168 @default.
• W3035922182 cites W2767840926 @default.
• W3035922182 cites W2792598062 @default.
• W3035922182 cites W2802538969 @default.
• W3035922182 cites W2907175560 @default.
• W3035922182 cites W2979759357 @default.
• W3035922182 cites W2982296199 @default.
• W3035922182 cites W2982564172 @default.
• W3035922182 cites W2985405196 @default.
• W3035922182 cites W2997747491 @default.
• W3035922182 cites W3000213223 @default.
• W3035922182 cites W3010908897 @default.
• W3035922182 cites W4211056322 @default.
• W3035922182 cites W4214721068 @default.
• W3035922182 doi "https://doi.org/10.1016/j.jcf.2020.06.012" @default.
• W3035922182 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32591294" @default.
• W3035922182 hasPublicationYear "2021" @default.
• W3035922182 type Work @default.
• W3035922182 sameAs 3035922182 @default.
• W3035922182 citedByCount "20" @default.
• W3035922182 countsByYear W30359221822020 @default.
• W3035922182 countsByYear W30359221822021 @default.
• W3035922182 countsByYear W30359221822022 @default.
• W3035922182 countsByYear W30359221822023 @default.
• W3035922182 crossrefType "journal-article" @default.
• W3035922182 hasAuthorship W3035922182A5002444114 @default.
• W3035922182 hasAuthorship W3035922182A5004678833 @default.
• W3035922182 hasAuthorship W3035922182A5006526044 @default.
• W3035922182 hasAuthorship W3035922182A5006649224 @default.
• W3035922182 hasAuthorship W3035922182A5007768330 @default.
• W3035922182 hasAuthorship W3035922182A5011296918 @default.
• W3035922182 hasAuthorship W3035922182A5014092783 @default.
• W3035922182 hasAuthorship W3035922182A5018306210 @default.
• W3035922182 hasAuthorship W3035922182A5018597500 @default.
• W3035922182 hasAuthorship W3035922182A5022125342 @default.
• W3035922182 hasAuthorship W3035922182A5022662991 @default.
• W3035922182 hasAuthorship W3035922182A5025602133 @default.
• W3035922182 hasAuthorship W3035922182A5028801971 @default.
• W3035922182 hasAuthorship W3035922182A5034520115 @default.
• W3035922182 hasAuthorship W3035922182A5050010383 @default.
• W3035922182 hasAuthorship W3035922182A5058612089 @default.
• W3035922182 hasAuthorship W3035922182A5070019992 @default.
• W3035922182 hasAuthorship W3035922182A5071401837 @default.
• W3035922182 hasAuthorship W3035922182A5072667906 @default.
• W3035922182 hasAuthorship W3035922182A5083476802 @default.
• W3035922182 hasAuthorship W3035922182A5087522944 @default.
• W3035922182 hasAuthorship W3035922182A5087945072 @default.
• W3035922182 hasBestOaLocation W30359221821 @default.
• W3035922182 hasConcept C126322002 @default.
• W3035922182 hasConcept C2776502428 @default.
• W3035922182 hasConcept C2776938444 @default.
• W3035922182 hasConcept C2778428886 @default.
• W3035922182 hasConcept C2778715236 @default.
• W3035922182 hasConcept C71924100 @default.
• W3035922182 hasConceptScore W3035922182C126322002 @default.
• W3035922182 hasConceptScore W3035922182C2776502428 @default.
• W3035922182 hasConceptScore W3035922182C2776938444 @default.
• W3035922182 hasConceptScore W3035922182C2778428886 @default.
• W3035922182 hasConceptScore W3035922182C2778715236 @default.
• W3035922182 hasConceptScore W3035922182C71924100 @default.
• W3035922182 hasFunder F4320323786 @default.
• W3035922182 hasIssue "2" @default.

• next